A new drug for rare skin diseases will be launched in China soon!

As the pace of human development continues to accelerate, more new changes have taken place in the environment that people rely on, and this has led to the continuous increase in the incidence of many diseases
.
Among them, the increasingly serious air pollution is leading to the increasing incidence of skin diseases
.
It is reported that in recent years, in addition to the continuous increase in the number of patients with skin diseases, the age of patients is also getting younger; and due to repeated skin diseases, patients delaying the disease, high treatment costs and other reasons, it is still bringing great disadvantages to the recovery of patients
.
At present, in order to solve the growing demand for dermatological drugs, a large number of pharmaceutical companies have begun to increase their layout in this field
.
Among them, it is worth mentioning that some pharmaceutical companies are constantly working in the field of rare skin diseases, and their new drugs are about to be launched in China
.
Recently, Boehringer Ingelheim announced that it has formally submitted a marketing application for the new immunological drug Spesolimab to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration for the treatment of the onset of generalized pustular psoriasis (GPP)
.
Data show that GPP is a rare, recurrent or persistent skin disease
.
The clinical manifestations are multiple aseptic pustules that are acute on the basis of erythema, which are densely and widely distributed, and the pustules merge to form a flaky pus lake, accompanied by fever, myalgia, leukocytosis and other poisoning symptoms
.
Spesolimab developed by Boehringer Ingelheim is an IL-36R monoclonal antibody that can block the action of interleukin-36 receptor (IL-36R) and is the first treatment of its kind under development
.
Interleukin-36 receptor is a signaling pathway in the immune system, which can play a role in many inflammatory diseases including GPP
.
It is understood that on June 25, due to its superior performance in phase I and phase II clinical trials, Spesolimab has just been recognized as a breakthrough therapy by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.
Treatment of generalized pustular psoriasis (GPP)
.
Statistics show that currently only 1 to 2 out of 100,000 people in China suffer from GPP
.
However, although the number of patients is scarce, due to the serious lack of public awareness of GPP in our country, this also delays the early diagnosis and treatment of many patients, and causes such diseases to be absent from the rare disease catalog.
Patients and their families bear huge mental and Economic pressure
.
In this context, the industry is very much looking forward to Spesolimab’s submission of a listing application in China as soon as possible, which will benefit more GPP patients
.
It is worth mentioning that Boehringer Ingelheim has been committed to the research and development of innovative drugs, and is also very concerned about the unmet needs of patients and their families
.
Therefore, it is currently developing the drug for the treatment of various immune disease indications.
In addition to GPP, it also includes palmoplantar pustulosis (PPP), Hidradenitis Suppurativa (HS) and special diseases.
Atopic dermatitis (AtD)
.
Among them, GPP is an indication with rapid development in research and development
.
The industry expects that with Boehringer Ingelheim’s continuous development of Spesolimab drugs, it will continue to promote the accelerated development of the entire GPP diagnosis and treatment field, improve the service level of GPP patients, increase the accessibility and affordability of new drugs, and benefit more GPP patients in China.
Promote the overall progress in the field of rare diseases in China and make due contributions
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina","tqq"," tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:", "viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu", "tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}};with(document)0[(getElementsByTagName('head ')[0]||body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js ?cdnversion='+~(-new Date()/36e5)]; Keywords: rare skin disease new drug, will be launched in China soon! ,Dermatological drugs,Pharmaceutical enterprisesNext: The reshuffle of the pharmaceutical retail market has intensified, and a group of pharmacies have left the market sadly! Previous post: Announcement on the evening of October 26 | A number of pharmaceutical companies disclosed three quarterly reports, and one released an annual performance forecast [Information Search] [Add to Favorites] [Tell a Friend] [Print This Article] [Close Window] A total of 0 similar information Article [View All] Related Comments js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; Keywords: rare skin disease new drug, will be launched in China soon! ,Dermatological drugs,Pharmaceutical enterprisesNext: The reshuffle of the pharmaceutical retail market has intensified, and a group of pharmacies have left the market sadly! Previous post: Announcement on the evening of October 26 | A number of pharmaceutical companies disclosed three quarterly reports, and one released an annual performance forecast [Information Search] [Add to Favorites] [Tell a Friend] [Print This Article] [Close Window] A total of 0 similar information Article [View All] Related Comments js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; Keywords: rare skin disease new drug, will be launched in China soon! ,Dermatological drugs,Pharmaceutical enterprisesNext: The reshuffle of the pharmaceutical retail market has intensified, and a group of pharmacies have left the market sadly! Previous post: Announcement on the evening of October 26 | A number of pharmaceutical companies disclosed three quarterly reports, and one released an annual performance forecast [Information search] [Add to favorites] [Tell friends] [Print this article] [Close window] Similar information total 0 Article [View All] Related Comments